The lack of significant between-group changes in DAS28-CRP at six months corroborates the results of a recent observational study reporting a significant reduction in a composite of incident coronary artery disease, stroke, heart failure-related hospitalization, or cardiovascular mortality (HR = 0.76, 95% CI 0.58 to 0.99, p = 0.04) in 2044 RA patients treated with methotrexate (mean age 63.9 years, 90% males, baseline DAS28-CRP 3.6) [56]. The gene discussed is CRP; the disease is coronary artery disorder.